恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗乙型肝炎肝硬化的临床疗效

目的 探讨恩替卡韦联合双歧杆菌乳杆菌三联活菌片治疗乙型肝炎肝硬化的临床疗效.方法 选取上饶市广信区血防站2018年2月—2020年1月收治的乙型肝炎肝硬化患者66例,按照随机数字表法分为对照组与观察组,各33例.对照组予以恩替卡韦片治疗,观察组在对照组基础上联合双歧杆菌乳杆菌三联活菌片治疗.2组均治疗3个月.比较2组治...

Clinical efficacy of entecavir combined with bifidobacterium lactobacillus triple viable bacteria tablet in the treatment of hepatitis B cirrhosis

Objective To explore the clinical efficacy of entecavir combined with bifidobacterium lactobacillus triple viable bacteria tablet in the treatment of hepatitis B cirrhosis.Methods A total of 66 cases of patients with hepatitis B cirrhosis were selected from February 2018 to january 2020 in Schistosomiasis Control Station,Guangxin District,Shangrao City,which were divided into control group and observation group according to the random number table,33 cases in each group.The control group was treated with entecavir tablets,the observation group was treated with bifidobacterium lactobacillus triple viable bacteria tablet on the basis of the control group.The treatment lasted for three months in both groups.Outcome(liver cancer,death,improvement),liver function indicators(ALT,TBiL,AIB)and serum liver fiber indicators(HA,LN,C-Ⅳ)before and after treatment were compared between the two groups,and the incidence of adverse reactions were observed. Results The improvement rate in the observation group was higher than control group(P<0.05).There was no significant difference in the incidence of liver cancer or death between the two groups(P>0.05).Before treatment,the differences in ALT,TBiL and AIB between the two groups were not statistically significant(P>0.05);after treatment,the observation group of ALT and TBiL were lower than control group,and AIB was higher than control group(P<0.05).Before treatment,the differences of HA,LN and C-Ⅳ between the two groups were not statistically significant(P>0.05);after treatment,HA,LN and C-Ⅳ levels in the observation group were lower than control group(P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion Entecavir combined with bifidobacterium lactobacillus triple viable bacteria tablet have an exact clinical effect for hepatitis B cirrhosis,which can improve the recovery rate of patients and effectively improve liver function and liver fiber indicators,with high safety.